2077 Article Views
Publication Date: 20 Apr 2009
Journal: Clinical Medicine Insights: Therapeutics
Jennifer L. Halsey
Specialty Pharmacy Coordinator, Aurora West Allis Medical Center, 8901 West Lincoln Avenue, West Allis, Wisconsin 53227.
Abstract
Nitazoxanide is a broad-spectrum agent active against several protozoa, helminths, and bacteria, including C. difficile and H. pylori. It is available as an oral tablet and suspension, both with adequate bioavailability. Nitazoxanide is associated with minimal side effects, has an acceptable safety profile, and has been classified as a pregnancy category B agent. It is 99% protein bound, which could result in drug interactions. It is the preferred agent for the treatment of Cryptospordiosis and Giardiasis in immunocompetent patients and has shown promise for the treatment of rotavirus, mild to moderate initial C. difficile infection, refractory C. difficile infection, Amoebiasis, Blastocystosis, and Taenia saginata.
Discussion
No comments yet...Be the first to comment.
In my opinion the review process in all the Libertas Academica journals I have had the privilege of reviewing papers for is second to none. The entire process is a click away and all the editorial staff are very cooperative. The papers that are submitted are of top quality and I am sure the journals will gain the status of high impact journals in a very short time.Dr C. Shekhar Mayanil (Children's Memorial Research Center, Chicago, IL, USA) What our authors say
Copyright © 2010 Libertas Academica Ltd (except open access articles and accompanying metadata and supplementary files.)